Once-weekly apraglutide showed consistent treatment effect across baseline demographics and disease characteristics in adults with short bowel syndrome with intestinal failure (sbs-if), according to new stars phase iii data from ironwood at acg 2024

Boston--(business wire)--ironwood pharmaceuticals, inc. (nasdaq: irwd), a gi-focused healthcare company, will present new findings at the american college of gastroenterology (acg) 2024 annual scientific meeting and postgraduate course from subgroup analyses of the primary endpoint of the pivotal phase iii clinical trial, stars, evaluating the treatment effect of apraglutide by baseline demographics and disease-specific characteristics in adults with short bowel syndrome with intestinal failure.
SBS Ratings Summary
SBS Quant Ranking